Nagi Bioscience secures CHF 12.4 Million investment in Series A round to revolutionize animal testing alternatives

The oversubscribed funding marked a significant step forward in the Swiss life sciences innovator's mission to advance the field of laboratory equipment.

Nagi Bioscience's first commercial product, SydLab™ One, was launched at the end of the first quarter of 2023 and has already gained significant traction in the biopharma and agrochemical R&D sectors, among others. "The enthusiastic support from our new investors reflects our belief in Nagi's potential to disrupt the drug discovery and toxicology testing markets. We are deeply grateful for their trust in our vision," said Matteo Cornaglia, CEO and co-founder of Nagi Bioscience. "This substantial investment is a testimony of the hard work, dedication, and passion of our incredible team and will be instrumental now in scaling up the commercial organization and operations while expanding R&D activities to strengthen Nagi’s portfolio of innovative products.”

The oversubscribed funding was led by top-tier venture capital firms including Swisscanto and imec.xpand, with the participation of Excellis Holding and existing investors Verve Ventures and Zürcher Kantonalbank.

The success journey of Nagi Bioscience has been driven by fostering close collaboration with its customers from the start. The collaborative mindset extends beyond product development; it's about co-creating solutions that genuinely meet the needs of the market. Nagi's ability to establish deep-rooted partnerships with customers has not only validated their current offerings but also has set a promising trajectory for the future.


Nagi Bioscience's Co-Founders: Laurent Mouchiroud (CSO) and Matteo Cornaglia (CEO)

The successful completion of the Series A round marks a remarkable milestone for Nagi Bioscience, opening doors to new markets, partnerships, and advancements to further disrupt the current biological testing paradigm. The company remains focused on its commitment to innovation, customer satisfaction, and delivering game-changing solutions that shape the future of next-generation drug discovery and chemical testing technologies.


Nagi Bioscience was ranked among the TOP 100 Swiss Startups in 2022 and 2020, won Venture Kick Stage 3 in 2019, and was selected as one of the participants for Venture Leaders Life Science in 2018.

"Venture Leaders Life Sciences Boston makes you unleash the power of your pitch in the USA!" said Matteo.